Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01808248 · ClinicalTrials.gov registry record · Phase 2

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

A Phase 2 study of Hepatitis C, sponsored by Gilead Sciences.

Completed
Registry status
Phase 2
Development phase
47
Enrollment target
1
Study location

NCT01808248: Completed Phase 2 study of Hepatitis C, sponsored by Gilead Sciences.

NCT01808248 is a Phase 2 study of Hepatitis C that has completed, run by Gilead Sciences. The registered enrollment target is 47 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01808248, a Phase 2 study of Hepatitis C, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 2
Development phase
47 participants
Enrollment target
1
Study location

Study Summary

This study is to evaluate the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF) in combination with peginterferon alfa 2a (PEG) and ribavirin (RBV) administered for 12 weeks in participants with chronic genotype 2 or 3 hepatitis C virus (HCV) infection who have previously failed prior treatment with an interferon-based regimen.

Primary Outcome

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, \< 15 IU/mL) at 12 weeks after stopping study treatment.

Conditions Studied

Hepatitis C

Interventions

  • DRUG SOF
  • DRUG RBV
  • DRUG PEG

Study Locations (1)

Texas

  • Alamo Medical Research - San Antonio

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2013-02
Est. Completion 2013-12
Phase Phase 2
Gilead Sciences

504 total trials

What the finished NCT01808248 record still lists

NCT01808248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 3 interventions - of which SOF is the first listed.

NCT01808248 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT01808248 about?

NCT01808248 is a clinical study titled "Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3". This study is to evaluate the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF) in combination with peginterferon alfa 2a (PEG) and ribavirin (RBV) administered for 12 weeks in participants with chronic genotype 2 or 3 hepatitis C virus (HCV) infection who have previously failed prior...

What is the current status of trial NCT01808248?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2013-02. Estimated completion is 2013-12.

What conditions does trial NCT01808248 study?

This clinical trial studies the following conditions: Hepatitis C.

What interventions are being tested in trial NCT01808248?

The interventions under investigation include: SOF (DRUG), RBV (DRUG), PEG (DRUG).

Who is sponsoring clinical trial NCT01808248?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01808248 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01808248's enrollment target sits among peer trials

47 76th of 106 higher than 30 of 106 other Hepatitis C trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03313011 · 47 participants

    The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

  • NCT03467516 · 47 participants · Phase 2

    Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

  • NCT03886662 · 47 participants · Phase 1

    A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

  • NCT04013802 · 47 participants · Phase 1

    TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01808248, the US trial registry maintained by the National Library of Medicine. NCT01808248 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.